Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Vericel

DB:ATQP
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ATQP
DB
$467M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The last earnings update was 43 days ago. More info.


Add to Portfolio Compare Print
  • Vericel has significant price volatility in the past 3 months.
ATQP Share Price and Events
7 Day Returns
6.1%
DB:ATQP
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-48.1%
DB:ATQP
-7.4%
DE Biotechs
-14.2%
DE Market
ATQP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Vericel (ATQP) 6.1% -27.7% -43.1% -48.1% 244.4% 152.3%
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • ATQP underperformed the Biotechs industry which returned -7.4% over the past year.
  • ATQP underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
ATQP
Industry
5yr Volatility vs Market

Value

 Is Vericel undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Vericel. This is due to cash flow or dividend data being unavailable. The share price is €8.516.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Vericel's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Vericel's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:ATQP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.22
NasdaqCM:VCEL Share Price ** NasdaqCM (2020-04-08) in USD $10.4
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Vericel.

DB:ATQP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:VCEL Share Price ÷ EPS (both in USD)

= 10.4 ÷ -0.22

-47.54x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vericel is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Vericel is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Vericel's expected growth come at a high price?
Raw Data
DB:ATQP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -47.54x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
52.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Vericel, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Vericel's assets?
Raw Data
DB:ATQP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $2.48
NasdaqCM:VCEL Share Price * NasdaqCM (2020-04-08) in USD $10.4
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:ATQP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:VCEL Share Price ÷ Book Value per Share (both in USD)

= 10.4 ÷ 2.48

4.2x

* Primary Listing of Vericel.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vericel is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Vericel's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Vericel has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Vericel expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
52.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Vericel expected to grow at an attractive rate?
  • Vericel's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Vericel's earnings growth is expected to exceed the Germany market average.
  • Vericel's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:ATQP Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:ATQP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 52.1%
DB:ATQP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 20.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:ATQP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:ATQP Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 343 79 1
2023-12-31 293 60 2
2022-12-31 212 32 4
2021-12-31 165 10 5
2020-12-31 122 -9 5
2020-04-08
DB:ATQP Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 118 -7 -10
2019-09-30 110 -8 -14
2019-06-30 102 -14 -18
2019-03-31 95 -1 -3
2018-12-31 91 0 -8
2018-09-30 83 -2 -13
2018-06-30 75 -9 -17
2018-03-31 73 -10 -15
2017-12-31 64 -13 -17
2017-09-30 57 -23 -26
2017-06-30 54 -22 -29
2017-03-31 50 -22 -31

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Vericel's earnings are expected to grow significantly at over 20% yearly.
  • Vericel's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:ATQP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Vericel Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:ATQP Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 1.54 1.54 1.54 1.00
2023-12-31 1.24 1.51 0.97 2.00
2022-12-31 0.68 1.23 0.41 4.00
2021-12-31 0.20 0.65 -0.24 5.00
2020-12-31 -0.20 0.09 -0.71 5.00
2020-04-08
DB:ATQP Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.22
2019-09-30 -0.32
2019-06-30 -0.42
2019-03-31 -0.08
2018-12-31 -0.20
2018-09-30 -0.34
2018-06-30 -0.49
2018-03-31 -0.44
2017-12-31 -0.52
2017-09-30 -0.84
2017-06-30 -1.04
2017-03-31 -1.24

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Vericel will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Vericel's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Vericel has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Vericel performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Vericel's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Vericel does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Vericel's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Vericel's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Vericel's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Vericel Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:ATQP Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 117.85 -9.67 61.14 30.39
2019-09-30 109.80 -13.92 58.45 30.19
2019-06-30 101.78 -18.46 56.04 30.21
2019-03-31 94.64 -3.32 51.57 12.88
2018-12-31 90.86 -8.14 49.01 13.60
2018-09-30 82.87 -13.09 45.50 14.17
2018-06-30 74.65 -17.43 41.11 13.97
2018-03-31 72.59 -15.17 38.16 13.21
2017-12-31 63.92 -17.29 35.61 12.94
2017-09-30 57.10 -25.76 33.35 13.62
2017-06-30 53.77 -28.96 32.18 14.14
2017-03-31 49.64 -31.47 29.79 15.23
2016-12-31 54.38 -27.15 27.39 15.30
2016-09-30 53.28 -25.64 25.21 18.44
2016-06-30 53.66 -23.17 23.87 18.74
2016-03-31 54.43 -22.08 23.01 18.05
2015-12-31 51.17 -23.08 22.48 18.89
2015-09-30 50.45 -20.34 21.34 17.28
2015-06-30 48.80 -22.66 19.88 21.37
2015-03-31 39.65 -24.96 17.38 22.37
2014-12-31 28.80 -25.93 13.27 21.26
2014-09-30 14.10 -26.30 10.28 18.39
2014-06-30 4.44 -21.49 7.08 12.56
2014-03-31 0.01 -21.58 5.46 11.47
2013-12-31 0.02 -20.97 5.88 14.70
2013-09-30 0.03 -24.56 5.88 17.80
2013-06-30 0.03 -28.17 7.01 21.94

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Vericel has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Vericel has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Vericel improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Vericel's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Vericel has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Vericel's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Vericel's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Vericel is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Vericel's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Vericel's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Vericel has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Vericel Company Filings, last reported 3 months ago.

DB:ATQP Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 111.09 0.00 69.72
2019-09-30 96.99 0.00 74.67
2019-06-30 88.54 0.00 66.01
2019-03-31 103.06 0.00 84.09
2018-12-31 102.23 0.00 82.92
2018-09-30 94.48 17.28 97.75
2018-06-30 90.60 17.26 94.97
2018-03-31 20.94 17.25 29.78
2017-12-31 22.54 17.24 26.86
2017-09-30 16.74 9.96 15.47
2017-06-30 13.97 10.16 14.04
2017-03-31 15.50 10.15 19.85
2016-12-31 24.71 10.13 22.98
2016-09-30 11.39 5.61 8.88
2016-06-30 17.11 2.36 9.84
2016-03-31 19.23 0.06 13.54
2015-12-31 22.13 0.07 14.58
2015-09-30 26.41 0.08 18.72
2015-06-30 30.24 0.09 20.22
2015-03-31 31.70 0.10 25.90
2014-12-31 35.64 0.11 30.34
2014-09-30 37.78 0.15 37.58
2014-06-30 2.79 2.50 7.26
2014-03-31 3.77 0.00 8.84
2013-12-31 3.89 0.00 8.06
2013-09-30 4.95 0.01 10.82
2013-06-30 1.84 0.02 4.49
  • Vericel has no debt.
  • Vericel has no debt compared to 5 years ago when it was 0.3%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Vericel has sufficient cash runway for more than 3 years based on current free cash flow.
  • Vericel has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of -15.1% each year.
X
Financial health checks
We assess Vericel's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Vericel has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Vericel's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Vericel dividends.
If you bought €2,000 of Vericel shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Vericel's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Vericel's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:ATQP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:ATQP Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Vericel has not reported any payouts.
  • Unable to verify if Vericel's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Vericel's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Vericel has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Vericel's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Vericel afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Vericel has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Vericel's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Nick Colangelo
COMPENSATION $5,385,527
AGE 55
TENURE AS CEO 7.1 years
CEO Bio

Mr. Dominick C. Colangelo, also known as Nick, Esq., has been the Chief Executive Officer and President at Vericel Corporation. since March 1, 2013 and served as its Treasurer since May 7, 2014. Mr. Colangelo served as Chief Accounting Officer at Vericel Corporation since May 7, 2014. He served as Managing Director of Lilly BioVentures and Lilly Venture Funds. Mr. Colangello was responsible for directing Lilly's venture investing activities. He led investments in Xenoport, NexCura, LLC, Zyomyx and Fast Track Systems. He has more than twenty years of executive management and corporate development experience in the biopharmaceutical industry, including nearly a decade with Eli Lilly and Company. He joined Lilly in 1995 after practicing tax law in New York and Washington, D.C. He served as the Chief Executive Officer of Promedior, Inc. from January 2009 to May 2012 and also served as its President until May 2012. He served as Consultant of Oscient Pharmaceuticals Corp. since December 2008. He served as an Executive Vice President of Corporate Development and Operations at Oscient Pharmaceuticals Corp. from February 2006 to December 2008 and Senior Vice President for Corporate Development and Operations from January 1, 2005 to February 2006. He led Oscient's licensing, partnering, merger and acquisition and strategic planning activities as well as the corporate quality and compliance, intellectual property and legal teams. He served with Eli Lilly and Company, as founding Managing Director of Lilly Ventures and Director of Strategy and Business Development for Lilly's Diabetes and Growth Disorders Products group. He has been Director of Vericel Corporation since March 2013. He joined Eli Lilly in 1995. He began his career as a practicing attorney. He serves as a Director at NexCura, LLC. He serves on the board of directors of the National Venture Capital Association Medical Industry Group. He served as Director of Promedior, Inc. from January 2009 to May 2012. He served as a Director of Hydra Biosciences Inc., Zyomyx, Inc. and CGI Pharmaceuticals, Inc. He serves Trustee of the National Childhood Cancer Foundation. He is graduate of the Duke University School of Law. He received his B.S.B.A. in Accounting, Magna Cum Laude, from the State University of New York at Buffalo and a J.D. degree, with Honors, from the Duke University School of Law.

CEO Compensation
  • Nick's compensation has increased whilst company is loss making.
  • Nick's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Vericel management team in years:

1.3
Average Tenure
56.5
Average Age
  • The average tenure for the Vericel management team is less than 2 years, this suggests a new team.
Management Team

Nick Colangelo

TITLE
CEO, President & Director
COMPENSATION
$5M
AGE
55
TENURE
7.1 yrs

Gerard Michel

TITLE
CFO & VP of Corporate Development
COMPENSATION
$2M
AGE
56
TENURE
5.8 yrs

Mike Halpin

TITLE
Chief Operating Officer
COMPENSATION
$2M
AGE
58
TENURE
0.8 yrs

Sean Flynn

TITLE
VP, General Counsel & Corporate Secretary
TENURE
0.4 yrs

Heidi Hassen

TITLE
Vice President of Human Resources

Jon Hopper

TITLE
Chief Medical Officer
AGE
57
TENURE
1.7 yrs

Roland DeAngelis

TITLE
Senior Vice President of Commercial Operations
TENURE
0.6 yrs
Board of Directors Tenure

Average tenure and age of the Vericel board of directors in years:

7.1
Average Tenure
61
Average Age
  • The tenure for the Vericel board of directors is about average.
Board of Directors

Robert Zerbe

TITLE
Chairman & Lead Director
COMPENSATION
$253K
AGE
68
TENURE
7.5 yrs

Nick Colangelo

TITLE
CEO, President & Director
COMPENSATION
$5M
AGE
55
TENURE
7.1 yrs

Alan Rubino

TITLE
Independent Director
COMPENSATION
$238K
AGE
64
TENURE
14.6 yrs

Heidi Hagen

TITLE
Independent Director
COMPENSATION
$230K
AGE
50
TENURE
6.7 yrs

Kevin McLaughlin

TITLE
Independent Director
COMPENSATION
$233K
AGE
63
TENURE
5.3 yrs

Mahendra Rao

TITLE
Member of Scientific Advisory Board
AGE
58
TENURE
10 yrs

Karen Hirschi

TITLE
Member of Scientific Advisory Board
TENURE
10 yrs

Joyce Frey-Vasconcells

TITLE
Member of Scientific Advisory Board

Steve Gilman

TITLE
Independent Director
COMPENSATION
$220K
AGE
66
TENURE
5.3 yrs

Paul Wotton

TITLE
Independent Director
COMPENSATION
$218K
AGE
59
TENURE
5.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Vericel's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Vericel has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. It markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to dilated cardiomyopathy. In addition, its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for debridement of severe thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.

Details
Name: Vericel Corporation
ATQP
Exchange: DB
Founded: 1989
$429,855,568
44,945,918
Website: http://vcel.com
Address: Vericel Corporation
64 Sidney Street,
Cambridge,
Massachusetts, 02139,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM VCEL Common Stock Nasdaq Capital Market US USD 04. Feb 1997
DB ATQP Common Stock Deutsche Boerse AG DE EUR 04. Feb 1997
Number of employees
Current staff
Staff numbers
241
Vericel employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 23:11
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/04/06
Last earnings filing: 2020/02/25
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.